ArticleDiabetology & metabolic syndrome2026
Association between the remnant cholesterol and the risk of new-onset chronic diseases: evidence from CHARLS.
Article in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRemnant cholesterol (RC), a key component of triglyceride-rich lipoproteins, is an established predictor of atherosclerotic cardiovascular disease. However, its longitudinal associations with the development of a broad spectrum of other chronic diseases, particularly in middle-aged and older populations, remain largely unexplored.
methodsThis nationwide prospective cohort study analyzed data from 8,828 adults (aged ≥ 45 years) in CHARLS. We employed Cox proportional hazards models to assess longitudinal associations between RC and 14 new-onset chronic conditions (ascertained via self-reported doctor diagnosis). Furthermore, interpretable machine learning models were developed and validated, with SHAP analysis used to quantify feature importance.
resultsIn fully adjusted Cox models, elevated RC was significantly associated with increased risks of new-onset diabetes, dyslipidemia, kidney disease, and liver disease (HRs ranging from 1.16 to 1.30, all P < 0.05). Among machine learning models, XGBoost demonstrated excellent predictive performance for all four conditions (AUCs ranging from 0.819 to 0.906). In SHAP analysis, RC was consistently identified as one of the top features associated with the model’s classification output, highlighting its potential utility in risk stratification.
conclusionUsing both Cox regression and machine learning in a large prospective cohort, this study identifies RC as a robust, independent risk factor for incident diabetes, dyslipidemia, kidney, and liver disease. Our findings support incorporating RC into routine screening to enhance clinical risk stratification and targeted interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.